Home Featured Page 170

Featured

Latest

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

PharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma

Filament Health and ATMA Journey Centers Announce Licensing Agreement

PT296 – Dr. David Luke – Vital Psychedelic Conversations

Reclaiming Ownership of Your Body With Psychedelics

Tackling Trauma with Pharmahuasca and DMT

World’s First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder...

PT295 – Sidarta Ribeiro – Dreams, LSD, and Biopiracy

Psychedelic Bulletin: Tracking LSD Patents; Psilocybin Effective for a Year in...

PT294 – Andrew Tatarsky, Ph.D. & Juliana Mulligan – Vital Psychedelic...

HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S....

1...169170171...292 Page 170 of 292

EDITOR PICKS

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

PharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma

Filament Health and ATMA Journey Centers Announce Licensing Agreement

PT296 – Dr. David Luke – Vital Psychedelic Conversations

Reclaiming Ownership of Your Body With Psychedelics

Tackling Trauma with Pharmahuasca and DMT

World’s First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder...

PT295 – Sidarta Ribeiro – Dreams, LSD, and Biopiracy

Psychedelic Bulletin: Tracking LSD Patents; Psilocybin Effective for a Year in...

PT294 – Andrew Tatarsky, Ph.D. & Juliana Mulligan – Vital Psychedelic...

HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S....

EDITOR PICKS

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY